FN1 and metastatic melanoma: Recently L19-IL2, an immunocytokine specific for the angiogenesis-associated B-fibronectin isoform able to selectively accumulate on tumor neovasculature, was investigated in a randomized phase II clinical trial in patients with metastatic melanoma in combination with dacarbazine or with L19-TNFα.